Shozo Matsuoka - Ono Pharmaceutical Executive
| OPHLF Stock | USD 9.90 0.00 0.00% |
Executive
Mr. Shozo Matsuoka was serving as Executive Officer and Director of NV Strategy Planning in ONO PHARMACEUTICAL CO., LTD. since 2017. He joined the Company in April 1985. His previous titles include Chief Director of Development, Director of Business Planning, Managing Director, Chief Director of Business Strategy and Senior Managing Director in the Company. since 2017.
| Age | 58 |
| Tenure | 8 years |
| Phone | 81 6 6263 5670 |
| Web | https://www.ono-pharma.com |
Ono Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1204 % which means that it generated a profit of $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1605 %, meaning that it generated $0.1605 on every $100 dollars invested by stockholders. Ono Pharmaceutical's management efficiency ratios could be used to measure how well Ono Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Ono Pharmaceutical Co has accumulated 8.65 B in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Ono Pharmaceutical has a current ratio of 4.08, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Ono Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Ono Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ono Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ono to invest in growth at high rates of return. When we think about Ono Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Susan MD | AstraZeneca PLC ADR | 59 | |
| Deborah Telman | Gilead Sciences | 59 | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Madeleine Roach | Sanofi ADR | 41 | |
| Catherine Adams | Bristol Myers Squibb | 54 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Flavius MD | Gilead Sciences | N/A | |
| Steffen Lang | Novartis AG ADR | 58 | |
| Shannon Klinger | Novartis AG ADR | 49 | |
| Monica Tijerina | Gilead Sciences | N/A | |
| Catherine Owen | Bristol Myers Squibb | 54 | |
| Vasant MD | Novartis AG ADR | 49 | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Jackson Egen | Gilead Sciences | N/A | |
| Bilal Piperdi | Gilead Sciences | N/A | |
| Steven Baert | Novartis AG ADR | 45 | |
| Roy Papatheodorou | Sanofi ADR | 47 | |
| John Tsai | Novartis AG ADR | 54 | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Ruth March | AstraZeneca PLC ADR | N/A | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 |
Ono Pharmaceutical Leadership Team
Elected by the shareholders, the Ono Pharmaceutical's board of directors comprises two types of representatives: Ono Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ono. The board's role is to monitor Ono Pharmaceutical's management team and ensure that shareholders' interests are well served. Ono Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ono Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyo Sagara, CEO and President and Representative Director | ||
| Hiromu Habashita, Executive Officer, Chief Director of Research | ||
| Katsuji Teranishi, Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | ||
| Toshihiro Tsujinaka, Executive Officer, Senior Director of Oncology in Main Sales Unit | ||
| Shozo Matsuoka, Executive Officer, Manager of R & D Strategy Office | ||
| Kiyoaki Idemitsu, Exec Officer | ||
| Hiroshi Ichikawa, Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | ||
| Isao Ono, Executive Officer, Manager of Environmental Management Office, Director | ||
| Yukio Tani, Executive Officer, Director of Public Relations | ||
| Toichi Takino, Executive Director of Corporate Devel. and Strategy and Corporate Officer |
Ono Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ono Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 488.31 M | |||
| Shares Owned By Insiders | 16.04 % | |||
| Shares Owned By Institutions | 44.41 % | |||
| Price To Earning | 18.12 X | |||
| Price To Book | 2.29 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.